Impact of HER2-ultralow heterogeneity and optimal threshold on trastuzumab deruxtecan (T-DXd) efficacy in metastatic breast cancer: A national multicenter cohort study (HEROIC).
Lists
Only you see this
Abstract
1117 Background: Trastuzumab deruxtecan (T-DXd) has been approved for patients (pts) with HER2-ultralow metastatic breast cancer (MBC). HER2 discordance commonly occurs between primary and metastatic lesions within the same patient; however, its incidence remains unknown in the HER2-ultralow era. Additionally, there is still controversy about which specimen to use to determine HER2-ultralow status and optimal threshold to guide T-DXd therapy. Methods: This national, multicenter cohort study included MBC pts treated with T-DXd (5.4 mg/kg) with HER2 status available for both primary tumors and matched metastases between January 2020 and October 2024 (NCT06551220). HER2 status was determined according to the DB-06 protocol. Pts were divided into three cohorts based on HER2 discordance patterns: cohort 1 (HER2-positive/low/ultralow in both primary and metastases), cohort 2 (HER2-positive/low/ultralow in primary and HER2-null in metastases), and cohort 3 (HER2-null in primary and HER2-positive/low/ultralow in metastases). Endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate, and clinical benefit rate. Results: From 24 centers nationwide, 3546 pts met the criteria and were included. The incidence of HER2 discordance between primary and matched metastases has changed across eras of HER2-positivity definitions: HER2-positive era (9.8%, K = 0.78), HER2-low era (25.0%, K = 0.39), and HER2-ultralow era (20.2%, K = 0.16). Among T-DXd-treated pts (n = 1052), a higher response rate was observed in cohort 1 (ORR = 55.7%) and cohort 3 (ORR = 53.1%) compared to cohort 2 (ORR = 13.0%). ORR is positively correlated with HER2 expression if metastatic lesions are used as the examined tissue (positive 62.9%, low 49.8%, ultralow 47.0%, null 13.0%). However, the correlation between ORR and HER2 expression is not significant when primary lesions were examined (positive 57.8%, low 41.5%, ultralow 54.4%, null 53.1%). Additionally, cohort 1 (mPFS = 11.6 mo, mOS = 30.7 mo) and cohort 3 (mPFS = 10.9 mo, mOS = 18.4 mo) exhibited significantly superior PFS and OS compared to cohort 2 (mPFS = 6.1 mo, mOS = 12.3 mo). Faint incomplete membrane staining percentage ≥5% in metastatic lesion was the best threshold to distinguish PFS (HR = 0.54, P = 0.02; mPFS, 11.4 vs 8.6 mo) and ORR (OR = 4.00, P = 0.01; 60% vs 27%) among HER2-ultralow MBC treated with T-DXd. Conclusions: A high HER2-ultralow discordance rate was observed between primary tumors and matched metastases. HER2 status in metastatic specimens more accurately predicts T-DXd efficacy compared to primary specimens. A staining threshold of ≥5% tumor cells in metastatic lesions may optimize T-DXd treatment in HER2-ultralow MBC. Therefore, re-evaluating HER2 status in metastatic lesions is recommended for T-DXd treatment decision.
BibTeX
@article{zou2025impact,
author = {Yutian Zou and Xinpei Deng and Yuan Zeng and Xiaoqian Hu and Quchang Ouyang and Qianjun Chen and Peijian Peng and Tao Wu and Weiwei Huang and Shien Cui and Jian Gu and Caiwen Du and Hongsheng Li and Yingkuan Shao and Xiaoxiang Guan and Xiumei Wang and Hong Hu and Xiaoyu Chen and Wenjun Yi and Xiaoming Xie and The HEROIC Study Investigator Group},
title = {{Impact of HER2-ultralow heterogeneity and optimal threshold on trastuzumab deruxtecan (T-DXd) efficacy in metastatic breast cancer: A national multicenter cohort study (HEROIC).}},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco.2025.43.16\_suppl.1117},
}Loading related content...